Detalles de la búsqueda
1.
The association between naloxone claims and proportion of independent vs. chain pharmacies: A longitudinal analysis of naloxone claims in the US.
J Am Pharm Assoc (2003)
; : 102093, 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38604474
2.
State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events.
Med Care
; 58(7): 610-616, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32205789
3.
State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients.
Med Care
; 58(12): 1111-1115, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32925468
4.
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Ann Intern Med
; 170(2): 90-98, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30557443
5.
State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.
Clin Infect Dis
; 66(10): 1618-1620, 2018 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29206910
6.
First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults.
J Gen Intern Med
; 33(12): 2156-2162, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30206790
7.
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis.
J Subst Use Addict Treat
; 158: 209254, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072387
8.
Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Drug Alcohol Depend
; 259: 111274, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643529
9.
Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.
Addict Sci Clin Pract
; 18(1): 34, 2023 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231479
10.
Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.
J Subst Use Addict Treat
; 146: 208943, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880906
11.
Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019.
Health Serv Res
; 58(5): 1141-1150, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37408299
12.
Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Addiction
; 118(3): 459-467, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305669
13.
Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
J Subst Abuse Treat
; 141: 108835, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35933942
14.
The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City.
Drug Alcohol Depend Rep
; 42022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36337350
15.
Diagnostic Coding of Elder Mistreatment: Results From a National Database of Medicare Advantage and Private Insurance Patients, 2011-2017.
J Appl Gerontol
; 41(4): 918-927, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34075830
16.
Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use.
Am J Prev Med
; 61(4): 537-544, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34233856
17.
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Addiction
; 116(12): 3444-3453, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33950535
18.
Design of a Payment Decision-Support Tool for Coordinated Specialty Care for Early Psychosis.
Psychiatr Serv
; 72(2): 180-185, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33267653
19.
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
Drug Alcohol Depend
; 215: 108221, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32777692
20.
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Addict Sci Clin Pract
; 15(1): 15, 2020 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32321570